Here are three things to know.
1. Through the agreement, Allergan will get exclusive access and the option to license up to five of Editas’ experimental eye treatments, according to the report.
2. Editas developed the eye treatments using the gene-editing technique CRISPR.
3. Allergan will pay $90 million upfront toward developing the drugs with Editas.
More articles on supply chain:
Do PBMs disrupt patient-physician relationships? 6 thoughts
Which news channel covers high drug costs the most?
6 things keeping supply chain leaders up at night
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
